Ultragenyx Pharmaceutical Inc. RARE
5 trading plans running, 16 Form 144 notices for $1.5M
10-Q, 10-K and Form 144What RARE's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Mar 11, 2025 to Jun 4, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in |
|---|---|---|---|
| Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy |
Adopted 10b5-1 plan | Jun 5, 2026 | 10-Q Aug 5, 2026 |
| Theodore Huizenga Senior Vice President and Chief Accounting Officer |
Adopted 10b5-1 plan | Jun 4, 2026 | 10-Q Aug 5, 2026 |
| John Pinion EVP, Chief Quality Officer and Translational Sciences |
Adopted 10b5-1 plan | May 19, 2026 | 10-Q Aug 5, 2026 |
| Karah Parschauer Executive Vice President, Chief Legal Officer and Corporate Affairs |
Adopted 10b5-1 plan | Mar 16, 2026 | 10-Q May 6, 2026 |
| Matthew Fust Director |
Adopted 10b5-1 plan | Mar 16, 2026 | 10-Q May 6, 2026 |
| Eric Crombez Chief Medical Officer |
Adopted 10b5-1 plan | Sep 5, 2025 | 10-Q Nov 5, 2025 |
| Howard Horn Chief Financial Officer and EVP, Corporate Strategy |
Adopted 10b5-1 plan | Sep 2, 2025 | 10-Q Nov 5, 2025 |
| John Pinion Translational Research and Chief Quality Officer |
Adopted 10b5-1 plan | May 9, 2025 | 10-Q Aug 6, 2025 |
| Emil D. Kakkis President and CEO, Director |
Adopted 10b5-1 plan | Mar 14, 2025 | 10-Q May 7, 2025 |
| Karah Parschauer Chief Legal Officer and Corporate Affairs |
Adopted 10b5-1 plan | Mar 11, 2025 | 10-Q May 7, 2025 |
| Howard Horn Chief Financial Officer |
Adopted 10b5-1 plan | Dec 9, 2024 | 10-K Feb 19, 2025 |
| Eric Crombez Chief Medical Officer |
Adopted 10b5-1 plan | Dec 3, 2024 | 10-K Feb 19, 2025 |
| Matthew Fust Board Member |
Adopted 10b5-1 plan | Nov 22, 2024 | 10-K Feb 19, 2025 |
| Corsee Sanders Board Member |
Adopted 10b5-1 plan | Nov 15, 2024 | 10-K Feb 19, 2025 |
| Shehnaaz Suliman Board Member |
Adopted 10b5-1 plan | Nov 8, 2024 | 10-Q Aug 6, 2025 |
| Shehnaaz Suliman Board Member |
Adopted 10b5-1 plan | Nov 8, 2024 | 10-K Feb 19, 2025 |
| Dennis Huang Chief Technical Operations Officer, Gene Therapy Research & Development |
Adopted 10b5-1 plan | May 7, 2024 | 10-Q Aug 2, 2024 |
| John Pinion Chief Quality Operations Officer and EVP, Translational Sciences |
Adopted 10b5-1 plan | May 7, 2024 | 10-Q Aug 2, 2024 |
| Eric Crombez EVP, Chief Medical Officer |
Adopted 10b5-1 plan | Mar 11, 2024 | 10-Q May 3, 2024 |
| Shehnaaz Suliman Board Member |
Adopted 10b5-1 plan | Mar 8, 2024 | 10-Q May 3, 2024 |
| Karah Parschauer EVP, Chief Legal Officer and Corporate Affairs |
Adopted 10b5-1 plan | Mar 5, 2024 | 10-Q May 3, 2024 |
| Emil Kakkis EVP, Chief Executive Officer and Director |
Adopted 10b5-1 plan | Mar 1, 2024 | 10-Q May 3, 2024 |
| Matthew Fust member of the Company’s Board of Directors |
Adopted 10b5-1 plan | Dec 7, 2023 | 10-K Feb 21, 2024 |
| Corsee Sanders member of the Company’s Board of Directors |
Adopted 10b5-1 plan | Nov 10, 2023 | 10-K Feb 21, 2024 |
| Shehnaaz Suliman Board Member |
Adopted 10b5-1 plan | – | 10-Q Nov 5, 2025 |
Show the other 17 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 5, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Sep 15, 2026 | THEODORE HUIZENGA Officer |
1,283 | $17K |
| Aug 3, 2026 | HOWARD HORN Officer |
4,696 | $117K |
| Jul 1, 2026 | HOWARD HORN Officer |
4,698 | $156K |
| Jun 15, 2026 | KARAH PARSCHAUER Officer |
3,799 | $93K |
| Jun 15, 2026 | CORAZON D. SANDERS Director |
2,000 | $50K |
| Jun 1, 2026 | HOWARD HORN Officer |
4,653 | $111K |
| May 18, 2026 | SHEHNAAZ SULIMAN Director |
5,740 | $144K |
| May 1, 2026 | HOWARD HORN Officer |
4,683 | $117K |
| Apr 1, 2026 | HOWARD HORN Officer |
4,683 | $98K |
| Mar 10, 2026 | KARAH PARSCHAUER Officer |
3,508 | $80K |
| Mar 6, 2026 | KARAH PARSCHAUER Officer |
6,018 | $129K |
| Mar 3, 2026 | HOWARD HORN Officer |
1,635 | $37K |
| Mar 2, 2026 | HOWARD HORN Officer |
3,119 | $70K |
| Feb 2, 2026 | HOWARD HORN Officer |
3,061 | $72K |
| Jan 2, 2026 | HOWARD HORN Officer |
3,150 | $72K |
| Dec 10, 2025 | HOWARD HORN Officer |
3,081 | $112K |
Show the other 8 notices
From the Form 144 XML filed with the SEC, since Dec 10, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.